Your browser doesn't support javascript.
loading
A novel stem cell therapy for hepatitis B virus-related acute-on-chronic liver failure
Zhu, Bing; You, Shaoli; Rong, Yihui; Yu, Qiang; Lv, Sa; Song, Fangjiao; Liu, Hongling; Wang, Huaming; Zhao, Jun; Li, Dongze; Liu, Wanshu; Xin, Shaojie.
Afiliação
  • Zhu, Bing; Medical School of Chinese PLA. CN
  • You, Shaoli; Fifth Medical Center of Chinese PLA General Hospital. Liver Failure Treatment and Research Center. CN
  • Rong, Yihui; Peking University International Hospital. Department of Infection and Liver Diseases. CN
  • Yu, Qiang; Fifth Medical Center of Chinese PLA General Hospital. Department of Interventional Therapy. CN
  • Lv, Sa; Fifth Medical Center of Chinese PLA General Hospital. Liver Failure Treatment and Research Center. CN
  • Song, Fangjiao; Fifth Medical Center of Chinese PLA General Hospital. Liver Failure Treatment and Research Center. CN
  • Liu, Hongling; Fifth Medical Center of Chinese PLA General Hospital. Liver Transplantation Center. CN
  • Wang, Huaming; Fifth Medical Center of Chinese PLA General Hospital. Department of Interventional Therapy. CN
  • Zhao, Jun; Fifth Medical Center of Chinese PLA General Hospital. Liver Failure Treatment and Research Center. CN
  • Li, Dongze; Fifth Medical Center of Chinese PLA General Hospital. Liver Failure Treatment and Research Center. CN
  • Liu, Wanshu; Fifth Medical Center of Chinese PLA General Hospital. Liver Failure Treatment and Research Center. CN
  • Xin, Shaojie; Medical School of Chinese PLA. CN
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;53(11): e9728, 2020. tab, graf
Article em En | LILACS, ColecionaSUS | ID: biblio-1132496
Biblioteca responsável: BR1.1
ABSTRACT
The aim of this study was to propose a stem cell therapy for hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) based on plasma exchange (PE) for peripheral blood stem cell (PBSC) collection and examine its safety and efficacy. Sixty patients (n=20 in each group) were randomized to PE (PE alone), granulocyte colony-stimulating factor (G-CSF) (PE after G-CSF treatment), and PBSC transplantation (PBSCT) (G-CSF, PE, PBSC collection and hepatic artery injection) groups. Patients were followed-up for 24 weeks. Liver function and adverse events were recorded. Survival analysis was performed. PBSCT improved blood ammonia levels at 1 week (P<0.05). The level of total bilirubin, international normalized ratio, and creatinine showed significant differences in the 4th week of treatment (P<0.05). The survival rates of the PE, G-CSF, and PBSCT groups were 50, 65, and 85% at 90 days (P=0.034). There was a significant difference in 90-day survival between the PE and PBSCT groups (P=0.021). The preliminary results suggested that PBSCT was safe, with a possibility of improved 90-day survival in patients with HBV-ACLF.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS / ColecionaSUS Assunto principal: Vírus da Hepatite B / Fator Estimulador de Colônias de Granulócitos / Hepatite B Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male Idioma: En Revista: Braz. j. med. biol. res / Rev. bras. pesqui. méd. biol Assunto da revista: BIOLOGIA / MEDICINA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS / ColecionaSUS Assunto principal: Vírus da Hepatite B / Fator Estimulador de Colônias de Granulócitos / Hepatite B Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male Idioma: En Revista: Braz. j. med. biol. res / Rev. bras. pesqui. méd. biol Assunto da revista: BIOLOGIA / MEDICINA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China País de publicação: Brasil